MDMX公司
癌症研究
肽
癌症治疗
平方毫米
对偶(语法数字)
癌症
药物开发
药理学
化学
生物化学
药品
医学
内科学
抑制器
基因
艺术
文学类
作者
Yong Seok Chang,Bradford J. Graves,Vincent Guerlavais,Christian Tovar,Kathryn E. Packman,Kwong-Him To,Karen A. Olson,Kamala P. Kesavan,Pranoti Gangurde,Aditi Mukherjee,Theresa Baker,Krzysztof Darłak,Carl D. Elkin,Zoran Filipovic,Farooq Qureshi,Hongliang Cai,Pamela W. Berry,Eric Feyfant,Xiangguo E. Shi,James Horstick
标识
DOI:10.1073/pnas.1303002110
摘要
Stapled α-helical peptides have emerged as a promising new modality for a wide range of therapeutic targets. Here, we report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates the p53 pathway in tumors in vitro and in vivo. Specifically, ATSP-7041 binds both MDM2 and MDMX with nanomolar affinities, shows submicromolar cellular activities in cancer cell lines in the presence of serum, and demonstrates highly specific, on-target mechanism of action. A high resolution (1.7-Å) X-ray crystal structure reveals its molecular interactions with the target protein MDMX, including multiple contacts with key amino acids as well as a role for the hydrocarbon staple itself in target engagement. Most importantly, ATSP-7041 demonstrates robust p53-dependent tumor growth suppression in MDM2/MDMX-overexpressing xenograft cancer models, with a high correlation to on-target pharmacodynamic activity, and possesses favorable pharmacokinetic and tissue distribution properties. Overall, ATSP-7041 demonstrates in vitro and in vivo proof-of-concept that stapled peptides can be developed as therapeutically relevant inhibitors of protein-protein interaction and may offer a viable modality for cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI